Novoste (novt) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Novoste (novt)

NOVT 130.94

+1.7%

Jan 9 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Oak Tree who wrote (68)	7/28/1999 10:37:00 PM
From: dr.john	Read Replies (2) of 100

Oak tree, I really appreciate your comments. I had the same doubts about the benefit of directionality in IVBT. Besides, does re-stenosis after angioplasy commonly predominate at tose radial segments which were most severely affected prior to PTCA (assuming an eccentric stenosis)? I doubt it, but I do not know it (after all, to my knowledge the re-stenosis of a previously eccentric stenosis is not a "topographic copy" of the previous stenosis; therefore directionality should not affect/improve the results of IVBT too much) On the other hand: those guys (at ESON) will have done their homework before developing "directional IVBT". Or it might just be a try to get their IVUS hooked to the latest hip (IVBT). Besides, what is your take on IVUS in general; I think the major problem is that a minute in the cath lab is very expensive and IVUS is viewed as a prolongation of the procedure, even though companies, such as ESON, claim that it is very quickly done in experienced hands... Another question: Which companies are developing the 192Ir device? Regards Dr John

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next